WilmerHale Represents Viamet Pharmaceuticals in Acquisition by NovaQuest Capital Management

WilmerHale Represents Viamet Pharmaceuticals in Acquisition by NovaQuest Capital Management

News

Viamet Pharmaceuticals (NC), Inc. (Viamet Pharmaceuticals) today announced that it has entered into an agreement with NovaQuest Capital Management, L.L.C. (NovaQuest Capital) for the acquisition of Viamet Pharmaceuticals, including the company's product candidate, VT-1161, which successfully completed Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis and onychomycosis. Upon closing of the acquisition, Viamet Pharmaceuticals will be a portfolio company of NovaQuest Capital, which will focus on further development of VT-1161 and related assets.

The WilmerHale deal team representing Viamet Pharmaceuticals includes Rosemary Reilly, Andrew Bonnes, Steve Barrett, Rob Burke, Kimberly Wethly, Mark Nylen, Andrea Sorrentino, Erin Garrity, Paul Jakubowski and Amit Tantri.

Read Viamet Pharmaceuticals' press release for more information.